1. Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?

   • Thomas M. Kuczmarski
   • Oreofe O. Odejide

   Health Economics (N Khera, Section Editor) 16 April 2021 Pages: 117 - 125

2. Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery

   • Tamara P. Miller
   • Richard Aplenc

   Topical Collection on Health Economics (N Khera, Section Editor) 30 March 2021 Pages: 126 - 131

3. The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond

   • Rahul Banerjee
   • Amar H. Kelkar
   • Naveen Pemmaraju

   Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 31 March 2021 Pages: 132 - 139

   

4. Enteropathy-Associated T cell Lymphoma

   • Zakiah Al Somali
   • Mehdi Hamadani
   • Mahmoud Aljurf

   T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 19 May 2021 Pages: 140 - 147

   

5. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma

   • Naimisha Marneni
   • Rajshekhar Chakraborty

   Multiple Myeloma (P Kapoor, Section Editor) 19 April 2021 Pages: 148 - 161

   

6. MRD Assessment in Multiple Myeloma: Progress and Challenges

   • Luca Bertamini
   • Mattia D’Agostino
   • Francesca Gay

   Multiple Myeloma (P Kapoor, Section Editor) 05 May 2021 Pages: 162 - 171

   

7. Progress in the Management of Smoldering Multiple Myeloma

   • Timothy M. Schmidt
   • Natalie S. Callander

   Multiple Myeloma (P Kapoor, Section Editor) 13 May 2021 Pages: 172 - 182

8. Antibody-Based Treatment Approaches in Multiple Myeloma

   • Hitomi Hosoya
   • Surbhi Sidana

   Multiple Myeloma (P Kapoor, Section Editor) 17 March 2021 Pages: 183 - 191

   

9. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches

   • Nicole R. Grieselhuber
   • Alice S. Mims

   Acute Myeloid Leukemias (U Borate, Section Editor) 18 March 2021 Pages: 192 - 206

10. IDH Inhibitors in AML—Promise and Pitfalls

    • Hannah McMurry
    • Luke Fletcher
    • Elie Traer

    Acute Myeloid Leukemias (U Borate, Section Editor) 30 April 2021 Pages: 207 - 217

    

11. Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job

    • Melanie Schwerdtfeger
    • Mohamed-Reda Benmebarek
    • Sebastian Kobold

    CART and immunotherapy (M Ruella and P Hanley, Section Editors) Open access 30 April 2021 Pages: 218 - 233